131 related articles for article (PubMed ID: 7654429)
1. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group.
Aamdal S; Wolff I; Kaplan S; Paridaens R; Kerger J; Schachter J; Wanders J; Franklin HR; Verweij J
Eur J Cancer; 1994; 30A(8):1061-4. PubMed ID: 7654429
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
Sulkes A; Smyth J; Sessa C; Dirix LY; Vermorken JB; Kaye S; Wanders J; Franklin H; LeBail N; Verweij J
Br J Cancer; 1994 Aug; 70(2):380-3. PubMed ID: 7914428
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Einzig AI; Schuchter LM; Recio A; Coatsworth S; Rodriquez R; Wiernik PH
Med Oncol; 1996 Jun; 13(2):111-7. PubMed ID: 9013474
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group.
Bruntsch U; Heinrich B; Kaye SB; de Mulder PH; van Oosterom A; Paridaens R; Vermorken JB; Wanders J; Franklin H; Bayssas M
Eur J Cancer; 1994; 30A(8):1064-7. PubMed ID: 7654430
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG).
Cerny T; Kaplan S; Pavlidis N; Schöffski P; Epelbaum R; van Meerbeek J; Wanders J; Franklin HR; Kaye S
Br J Cancer; 1994 Aug; 70(2):384-7. PubMed ID: 7914429
[TBL] [Abstract][Full Text] [Related]
7. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Verweij J; Catimel G; Sulkes A; Sternberg C; Wolff I; Aamdal S; van Hoesel Q
Eur J Cancer; 1995; 31A Suppl 4():S21-4. PubMed ID: 7577101
[TBL] [Abstract][Full Text] [Related]
8. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.
Smyth JF; Smith IE; Sessa C; Schoffski P; Wanders J; Franklin H; Kaye SB
Eur J Cancer; 1994; 30A(8):1058-60. PubMed ID: 7654428
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
[TBL] [Abstract][Full Text] [Related]
10. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Mertens WC; Eisenhauer EA; Jolivet J; Ernst S; Moore M; Muldal A
Ann Oncol; 1994 Feb; 5(2):185-7. PubMed ID: 7910480
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Forsyth P; Cairncross G; Stewart D; Goodyear M; Wainman N; Eisenhauer E
Invest New Drugs; 1996; 14(2):203-6. PubMed ID: 8913841
[TBL] [Abstract][Full Text] [Related]
13. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
[TBL] [Abstract][Full Text] [Related]
14. Optimal use of docetaxel (Taxotere): maximizing its potential.
Burris HA
Anticancer Drugs; 1996 Aug; 7 Suppl 2():25-8. PubMed ID: 8862707
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
16. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer.
Latreille J; Cormier Y; Martins H; Goss G; Fisher B; Eisenhauer EA
Invest New Drugs; 1996; 13(4):343-5. PubMed ID: 8824354
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in stage III and IV non-small cell lung cancer.
Rigas JR
Eur J Cancer; 1995; 31A Suppl 4():S18-20. PubMed ID: 7577100
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center.
Kaye SB; Piccart M; Aapro M; Kavanagh J
Eur J Cancer; 1995; 31A Suppl 4():S14-7. PubMed ID: 7577099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
